Literature DB >> 30551526

Azadirachta indica inhibits key enzyme linked to type 2 diabetes in vitro, abates oxidative hepatic injury and enhances muscle glucose uptake ex vivo.

Olakunle Sanni1, Ochuko L Erukainure1, Chika I Chukwuma2, Neil A Koorbanally3, Collins U Ibeji4, Md Shahidul Islam5.   

Abstract

The progression of secondary complications in type 2 diabetes (T2D) has been linked to oxidative stress caused by hyperglycemia. Therefore, the control of hyperglycemia is the main target in the treatment of diabetes. The present study investigated the scavenging and ameliorative potentials of different fractions of Azadirachta indica (A. indica) ethanol stem bark extract in Fe2+-induced oxidative injury in hepatic tissue as well as their ability to inhibit enzymes linked to diabetes and in enhancing muscle glucose uptake via some in vitro and ex vivo experimental models. The results revealed that the butanol fraction of the extract showed a significantly (p < 0.05) higher DPPH scavenging activity than the other fractions (IC50 0.0154 μg/mL), while the aqueous fraction showed the highest FRAP activity (IC50 25.32 μg/mL). Although all the fractions ameliorated Fe2+-induced oxidative injury in hepatic tissue by significantly reducing malondialdehyde (MDA) concentration in a dose dependent manner, the butanol fraction showed the highest activity in this regard. In addition, the activities of catalase and superoxide dismutase (SOD) were significantly improved by the butanol and dichloromethane fractions. Butanol and ethyl acetate fractions showed the highest inhibitory effect on α-glucosidase (IC50 0.23 μg/mL) and α-amylase (IC50 14.79 μg/mL) activities, respectively. Although all the fractions significantly improved glucose uptake in psoas muscle with or without insulin, the butanol fraction showed the highest activity (GU50 6.22 μg/mL) in this regard. Gas chromatography-mass spectroscopy (GC-MS) analysis of the fractions revealed the presence of sistosterol, stigmasterol, campestrol, squalene, nimbiol among others. Molecular docking of some of these compounds with AMP-activated protein kinase (α-AMPK), α-amylase and α-glucosidase showed a positive interaction. These results suggest that the butanol and ethyl acetate fractions of A. indica may have bioactive compounds with antidiabetic potentials.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antidiabetic; Azadirachta indica; Glucose uptake; Oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 30551526     DOI: 10.1016/j.biopha.2018.10.171

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  4 in total

1.  Evaluation of the Effect of an Aqueous Extract of Azadirachta indica (Neem) Leaves and Twigs on Glycemic Control, Endothelial Dysfunction and Systemic Inflammation in Subjects with Type 2 Diabetes Mellitus - A Randomized, Double-Blind, Placebo-Controlled Clinical Study.

Authors:  Usharani Pingali; Mohammed Abid Ali; Srinivas Gundagani; Chandrasekhar Nutalapati
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-17       Impact factor: 3.168

2.  Cannabis sativa L. (var. indica) Exhibits Hepatoprotective Effects by Modulating Hepatic Lipid Profile and Mitigating Gluconeogenesis and Cholinergic Dysfunction in Oxidative Hepatic Injury.

Authors:  Ochuko L Erukainure; Motlalepula G Matsabisa; Veronica F Salau; Sunday O Oyedemi; Omolola R Oyenihi; Collins U Ibeji; Md Shahidul Islam
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

3.  Anti-hyperglycemic and ameliorative effect of concentrated hot water-infusion of Phragmanthera incana leaves on type 2 diabetes and indices of complications in diabetic rats.

Authors:  Olakunle Sanni; Ochuko L Erukainure; Olajumoke Oyebode; Md Shahidul Islam
Journal:  J Diabetes Metab Disord       Date:  2019-11-14

4.  GC-MS Analysis and Inhibitory Evaluation of Terminalia catappa Leaf Extracts on Major Enzymes Linked to Diabetes.

Authors:  Franklyn Nonso Iheagwam; Emmanuel Nsedu Israel; Kazeem Oyindamola Kayode; Opeyemi Christianah De Campos; Olubanke Olujoke Ogunlana; Shalom Nwodo Chinedu
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-05       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.